Posted by Michael Wonder on 28 Sep 2022
Citius Pharmaceuticals submits biologics license application to the US Food and Drug Administration for denileukin diftitox for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma
28 September 2022 - Citius Pharmaceuticals today announced that the Company has submitted a biologics license application to the US FDA for denileukin diftitox (I/ONTAK), an engineered IL-2-diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.
I/ONTAK is a purified and more bioactive formulation of previously FDA approved denileukin diftitox.
